Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 7, 2021BloodOpen Access

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

View Full Paper
Ask AI
Bookmark
Share

Authors

RARanjana H. AdvaniRutgers, The State University of New JerseyAMAlison J. MoskowitzMemorial Sloan Kettering Cancer CenterNBNancy L. BartlettBoston University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Advani et al. (2021) studied this question.

synapsesocial.com/papers/69ffc679b124fe5819859ceehttps://doi.org/10.1182/blood.2020009178
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma2018 · 257 citations
  2. 2Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma2017 · 61 citations
  3. 3Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma2017 · 139 citations
  4. 4Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,739 citations
  5. 5Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma2015 · 761 citations